EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dietary polyphenols in colorectal cancer – Mechanisms, clinical evidence, and bioavailability of curcumin, resveratrol, and epigallocatechin-3-gallate: A review

Haifa A Alqahtani

Biomolecules and Biomedicine · 30.07.2026

DOI: 10.17305/bb.2026.14667 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 30.07.2026. Verfasst von Haifa A Alqahtani. Beteiligte Einrichtung: Department of Biology, College of Science, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dietary polyphenols have attracted considerable interest as potential preventive and therapeutic agents in colorectal cancer (CRC), although their clinical value remains uncertain. This narrative review aimed to critically evaluate the mechanistic, epidemiological, and clinical evidence for curcumin, resveratrol, and epigallocatechin-3-gallate (EGCG), with particular emphasis on the gap between preclinical activity and human efficacy. PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language studies published from January 2000 to January 2026, including in vitro and animal investigations, epidemiological studies, and clinical trials. Preclinical evidence consistently showed that these polyphenols inhibit nuclear factor kappa B (NF-κB), phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR), signal transducer and activator of transcription 3 (STAT3), and Wnt/β-catenin signaling, while promoting apoptosis, antioxidant responses, and suppression of inflammation, proliferation, angiogenesis, and metastasis. These effects were associated with reduced tumor burden in animal models. Epidemiological studies suggested modest protective associations, particularly for green tea consumption, but findings were inconsistent, frequently confounded, and of limited generalizability. Human trials predominantly demonstrated biomarker modulation, whereas effects on adenoma recurrence were mixed and no consistent benefits were observed for tumor regression, recurrence, progression-free survival, or overall survival. Clinical translation is further limited by poor absorption, rapid metabolism, uncertain activity of metabolites, formulation variability, and potential hepatotoxicity and drug interactions, although high local colorectal exposure may remain biologically relevant. Curcumin, resveratrol, and EGCG therefore show strong mechanistic potential but cannot currently be recommended as stand-alone CRC therapies. They should be regarded as investigational preventive or adjunctive agents pending adequately powered randomized trials using standardized formulations, optimized dosing, and clinically meaningful endpoints.

Autor:innen und Institutionen

  • Department of Biology, College of Science, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

Zitieren

APA

Alqahtani, H. A. (2026). Dietary polyphenols in colorectal cancer – Mechanisms, clinical evidence, and bioavailability of curcumin, resveratrol, and epigallocatechin-3-gallate: A review. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.14667

Vancouver

Alqahtani HA. Dietary polyphenols in colorectal cancer – Mechanisms, clinical evidence, and bioavailability of curcumin, resveratrol, and epigallocatechin-3-gallate: A review. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.14667

BibTeX
@article{Alqahtani2026,
  author = {Alqahtani, Haifa A},
  title = {Dietary polyphenols in colorectal cancer – Mechanisms, clinical evidence, and bioavailability of curcumin, resveratrol, and epigallocatechin-3-gallate: A review},
  journal = {Biomolecules and Biomedicine},
  year = {2026},
  doi = {10.17305/bb.2026.14667}
}
Kostenlos starten →